Tracked deals
73
73 tracked deals across 2026.
Tracked deals
73
73 tracked deals across 2026.
Buyer mix
Strategic-led
52 strategic · 24 pe
Top trend
Volume peaked in 2021
223 tracked deals announced in 2021.
Buyer Snapshot
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Boston Scientific Corporation | 2 | Large medical device company focused on cardiovascular an... | Strategic |
| Johnson & Johnson | 2 | Multinational healthcare company with expanding cardiovas... | Strategic |
| Medtronic plc | 2 | Global healthcare technology company with major medtech b... | Strategic |
| ALR Technologies | 1 | Diabetes management company developing the ALRT Diabetes ... | Mixed |
| AMETEK, Inc. | 1 | Industrial technology provider with advanced analytical, ... | Strategic |
| AP Technologies | 1 | Singapore-headquartered contract manufacturer focused on ... | Strategic |
| ARCHIMED | 1 | Healthcare‑focused investment firm and strategic financia... | PE |
| Advanced Sterilization Products (ASP) | 1 | Fortive’s infection-prevention business that designs and ... | Strategic |
| Agilent Technologies Inc. | 1 | Global analytical and clinical laboratory technologies co... | Strategic |
| Ally Bridge Group | 1 | Global healthcare-focused investment firm investing acros... | PE |
Last 10 years
Supporting Data
MiMedx Group (MIMEDX) has entered into a definitive merger agreement to acquire Sanara MedTech for an enterprise value of approximately $350 million. Under the terms, MIMEDX will buy all outstanding Sanara shares for $33.00 in cash and 0.4735 shares of MIMEDX stock per share, expected to close by year-end subject to approvals and customary conditions.
Goldman Sachs Alternatives has entered into a definitive agreement to acquire a majority stake in Numantec from White Bridge Investments and other existing shareholders. The transaction is expected to close in the fourth quarter of 2026, subject to regulatory approvals. Numantec is an Italian medtech company that develops, manufactures, and distributes infusion medical devices and serves the full infusion care pathway.
KMM Group, a precision contract manufacturer for the medical device industry, announced the completion of an investment from RS2 Healthcare Partners. J. Mark King was appointed President and CEO, and co-founders John Shegda (CTO) and Eric Wilhelm (EVP of Business Transformation and Organizational Capability) will lead engineering/technology and operational excellence initiatives respectively. Financial terms were not disclosed.
DePuy Synthes, the orthopedics division of Johnson & Johnson MedTech, acquired Expanding Innovations, Inc., a commercial-stage medical technology company focused on expandable interbody cage systems for spine surgery. The acquisition adds proprietary non-screw-based expandable cage technology to strengthen DePuy Synthes’ spine implant portfolio in the lumbar fusion market.
Steel Partners Holdings L.P. offered to acquire 100% of InMode Ltd. for $16.75 per share in cash, representing a 20% premium to InMode’s “unaffected” share price of $13.95. The offer also allows existing shareholders to roll over up to 40% of their equity into the post-transaction company.
Azenta has completed the sale of its B Medical Systems business to Thelema S.à r.l., closing the transaction on July 1, 2026 after all required conditions were satisfied. Azenta sold B Medical Systems for a fixed $63 million in cash, with $35 million financed through a short-term secured vendor loan provided by an Azenta subsidiary to Thelema.
Pacira BioSciences has agreed to divest its iovera° business to Zimmer Biomet for up to $140 million, consisting of $70 million upfront plus up to an additional $70 million in revenue-based milestone payments. The iovera° system is an FDA-cleared, drug-free medical device that relieves pain through cryoneurolysis.
Gainline Capital Partners announced that its portfolio company, M&M International, has acquired KC Tech. The acquisition will expand M&M’s medical-grade stainless-steel tubing manufacturing capabilities by adding KC Tech’s complementary larger-diameter tubing line, strengthening M&M’s ability to serve medical device customers with specialized tubing solutions.
ALR Technologies entered into a letter of intent to acquire 100% of CGM Medical Technology Singapore and to acquire certain assets of CGM Medical Technology Shenzhen. The deal values CGM Medical Singapore at a total purchase consideration including 200 million ordinary shares and $45 million, with additional contingent earn-out payments tied to free cash flow. ALR Technologies plans to use the acquired technology and licenses to build a manufacturing facility in the Johor-Singapore Special Economic Zone and expects to sign definitive agreements by late July 2026 (Singapore) and late August 2026 (Shenzhen).
InMode said its board received an unsolicited proposal from M.N. Business Strategy to acquire all outstanding ordinary shares not already owned by M.N. Business Strategy and its affiliates. The proposed merger would value the shares at $16.20 per share in cash, and InMode has formed a special committee of independent directors to evaluate the offer.
Advanced Sterilization Products (ASP), part of Fortive’s Infection Prevention group, acquired a majority share of UV Smart, a European leader in UV-C high level disinfection technology. The acquisition is intended to expand ASP’s infection-prevention clinical solutions portfolio and accelerate global adoption of UV Smart’s disinfection products across Europe and North America.
Spring Loaded Technology, a Canadian orthopedic bracing and mobility solutions company, announced a strategic investment from Plaza Capital to support its next phase of growth. The funding is intended to accelerate international expansion (including the United States and Europe), further R&D, and continued advancement of evidence-based mobility solutions.
CVC Catalyst III agreed to acquire a majority stake in WillowWood Holdings Inc., with CVC Catalyst becoming the majority investor alongside Blue Sea Capital, the Arbogast family, and WillowWood management (who will reinvest). The parties expect closing in the third quarter of 2026, subject to regulatory approvals, and plan to use the partnership to accelerate product innovation and international expansion—especially in Europe.
Spectrum Vascular, backed by SK Capital Partners, announced it has acquired Piccolo Medical, a San Francisco-based developer of catheter guidance technologies. The deal will integrate Piccolo’s 510(k)-cleared real-time catheter navigation and location products with Spectrum’s existing vascular access portfolio to accelerate commercialization and support a next-generation guided vascular access standard of care.
Galmed Pharmaceuticals entered into a definitive agreement to acquire Colospan, a commercial-stage colorectal surgery medical device company, positioning Galmed as a GI-focused medtech and biopharmaceutical platform. Colospan’s CG-100 intraluminal bypass device is CE marked under the EU MDR and has an active U.S. pivotal IDE program, while Galmed has restructured acquisition terms and consummated the deal after the announcement of revised anti-dilutive payment and earnout provisions.
Novanta Inc. entered into a definitive agreement to acquire Riverpoint Medical from Arlington Capital Partners for $1.2 billion upfront cash plus a $250 million milestone payment in Q1 2027, for total value up to $1.45 billion. The deal is expected to close in Q3 2026, subject to customary regulatory approvals and closing conditions.
Lineus Medical, developer of the SafeBreak Vascular breakaway IV device, completed a strategic recapitalization with KMF Investments. The transaction, finalized at the start of 2026, establishes KMF as a stable financial backer and provides resources to accelerate SafeBreak Vascular adoption and growth in the United States.
ResMed completed its acquisition of Noctrix Health, a medical device company developing wearable therapeutics for chronic neurological disorders. The deal expands ResMed’s clinical sleep health portfolio with Noctrix’s Nidra Tonic Motor Activation (TOMAC) therapy for moderate-to-severe Restless Legs Syndrome (RLS), with Noctrix becoming a wholly owned subsidiary. The acquisition was previously announced as a definitive merger agreement to acquire Noctrix for $340 million, expected to close on or around June 1, 2026.
Johnson & Johnson acquired Atraverse Medical, strengthening its J&J MedTech cardiac electrophysiology portfolio. The acquisition follows the May 15, 2026 close and is referenced in connection with medtech founder John Slump’s subsequent launch of Metis MedTech.
Olympus signed a definitive agreement to acquire BioProtect for $270 million to expand its urology and oncology technology portfolio for prostate cancer care. The deal is expected to close by the end of Q2 2026, subject to customary closing conditions, with portions of the purchase price held in escrow tied to uninterrupted operation.
AP Technologies announced the acquisition of Blueacre Technology, a Dundalk, Ireland-based specialist in laser micromachining and nitinol processing for the medical device industry. The deal expands AP Technologies’ vertically integrated catheter platform by adding nitinol and precision laser processing capabilities and establishes AP Technologies’ first European operation in Ireland.
Atreon Orthopedics and RenovoDerm have merged to form Atreon Orthopedics, Inc., combining synthetic biomaterial technologies for tissue repair and remodeling. The combined company aims to scale its Autobiologic platform technology across orthopedic, trauma, sports medicine, reconstructive, foot and ankle, and complex wound applications.
Endologix, a privately held medical device company, announced it will acquire the Pounce Thrombectomy System from Surmodics. The FDA-cleared, fully mechanical peripheral thrombectomy platform is intended to complement Endologix’s existing vascular intervention portfolio and expand the continuum of care for patients with peripheral vascular disease.
Everis Medical, a Kalamazoo, Michigan-based medical device company focused on otolaryngology and airway management, announced the acquisition of Hood Laboratories. The deal expands Everis’ portfolio of ENT, airway, and thoracic devices and establishes a meaningful entry into airway management.
BellaMia Technologies and Dominion Aesthetic Technologies completed a strategic merger valued at $200 million, combining their laser and robotic medical aesthetics technologies. The merged company will operate under the BellaMia Technologies name with Janet Campbell as CEO, aiming to expand commercial reach and accelerate product development across body contouring and skin rejuvenation.
Stryker completed its acquisition of Amplitude Vascular Systems, a privately held medical device company developing a next-generation intravascular lithotripsy (IVL) platform for calcified peripheral arterial disease (PAD). The deal was announced April 13, 2026 and closed May 7, 2026; financial terms were not disclosed in the MedDeviceGuide account, though other sources cite a value of up to $835 million.
Boston Scientific Corporation invested $1.5 billion for an approximately 34% equity stake in privately held MiRus LLC. Under the investment agreement, Boston Scientific received an exclusive option to acquire MiRus’s SIEGEL balloon-expandable TAVR system business for up to $3 billion in additional cash payments, subject to clinical and regulatory milestones and closing conditions.
Artivion, Inc. has completed the acquisition of Endospan Ltd., following U.S. FDA PMA approval of the NEXUS Aortic Arch System. The deal includes a $135 million upfront net purchase price (plus purchase price adjustments/offsets for previously provided loans) and potential additional consideration up to $200 million tied to U.S. commercial performance over the next two years.
Charlesbank-backed Tecomet and Nordic-backed Orchid Orthopedic Solutions have completed their merger to create a scaled global manufacturing platform serving medical device customers. The combination brings together manufacturing capabilities across orthopedic and related medtech end markets.
Drummond Scientific Company announced it has acquired Accu-Glass, LLC, a St. Louis-based manufacturer of high-precision glass capillaries used in medical and diagnostic applications. Accu-Glass will operate as a wholly owned subsidiary with employees retained and operations continuing at its current facility.
vVARDIS Holding AG announced a strategic minority investment from funds managed by Apollo Global Management to support the company’s global expansion. The funding is intended to accelerate the commercial rollout of vVARDIS’ non-invasive Curodont peptide-based dental treatment, with a focus on scaling adoption across the United States and Europe.
Johnson & Johnson entered into a definitive agreement to acquire Atraverse Medical, a privately held medtech company developing the HOTWIRE Transseptal Access System for left-heart access during cardiac electrophysiology procedures. The deal is expected to close in Q2 2026, subject to customary closing conditions, with financial terms not disclosed.
Bioretec Oy disclosed managers’ transaction activity indicating that Stephen Industries Inc Oy, a closely associated party of board member Kustaa Poutiainen, subscribed for shares outside a trading venue. The transaction details were reported with an aggregated share volume and very low nominal prices per unit.
Medtronic plc has completed its acquisition of CathWorks, a privately held medical device company focused on transforming how coronary artery disease is diagnosed and treated. The deal is valued at $585 million, with potential undisclosed earn-out payments, and enhances Medtronic’s interventional cardiology portfolio via the CathWorks FFRangio System.
Stereotaxis entered into a definitive agreement to acquire Robocath, a venture-backed developer of robotic technologies for interventional cardiology and neurointerventions. The deal is expected to close in mid-2026, with consideration including a $20 million upfront payment and up to $25 million in contingent payments tied to regulatory and commercial milestones.
Avanos Medical entered into a definitive all-cash agreement to be acquired by affiliates of American Industrial Partners (AIP) in a transaction valued at approximately $1.272 billion. Under the terms, Avanos stockholders will receive $25.00 per share, a premium of 72.1% to the April 13, 2026 closing price, and the deal is expected to close in the second half of 2026 subject to customary conditions.
Bioness Medical, Inc. announced the acquisition of the PoNS (Portable Neuromodulation Stimulator) System product line. The deal expands Bioness’s neurorehabilitation platform from functional electrical stimulation (FES) into non-invasive central neuromodulation delivered via the tongue, supporting multi-modal treatment for patients with gait and balance disorders.
Avista Healthcare Partners acquired Bentec Medical, a Woodland, California manufacturer of complex silicone-based medical device components and finished goods. The deal was announced April 8, 2026, and financial terms were not disclosed.
A Neumann & Associates, LLC announced the closing of the sale of a medical device manufacturer in the Philadelphia metro region in a transaction valued at $6 million. The company described the target as a medical device manufacturer with machining capabilities, significant operating margins, and nationwide/international sales, and noted a transition period under the new owner.
Merit Medical Systems acquired View Point Medical, Inc. in a transaction valued at approximately $140 million to expand its therapeutic oncology portfolio. Under the terms of the deal, Merit will pay $90 million in cash at closing plus two additional $25 million payments due on the first and second anniversaries, and View Point will become a wholly owned subsidiary of Merit.
Zynex, Inc. has been acquired by Altivera Medical Holdings, LLC in a deal approved by the U.S. Bankruptcy Court for the Southern District of Texas. The acquisition follows Zynex’s Chapter 11 restructuring and resolution of pending government investigations.
Thrombolex, Inc., a commercial-stage medical device company focused on pharmaco-mechanical lysis for thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed. The funding is intended to expand U.S. commercialization and advance clinical evidence generation for its FDA-cleared BASHIR Endovascular Catheter (BEC) platform for pulmonary embolism and other VTE indications.
Mechanix Wear, backed by Gryphon Investors, acquired OTEX, a developer and manufacturer of tech-enabled personal protective equipment (PPE) featuring patented safety and air-quality/cooling technologies. OTEX CEO Jake Weidert will remain with the organization as Vice President of Technology and Materials, and OTEX will operate under Mechanix Wear’s Chicago Protective Apparel division; transaction terms were not disclosed.
H&T Presspart, a division of the Heitkamp Thumann Group, acquired a majority stake in Plas-Tech Engineering. The transaction closed in November 2025 and expands H&T Presspart’s manufacturing footprint into the United States by adding Plas-Tech’s medical device manufacturing site in Lake Geneva, Wisconsin.
Medtronic entered into a definitive agreement to acquire Scientia Vascular in a $550 million deal, with customary adjustments and potential earn-out/milestone payments. The acquisition combines Scientia’s neurovascular access devices (guidewires and catheters) with Medtronic’s existing neurovascular therapeutic portfolio to support faster and more reliable treatment for complex stroke cases.
Agilent Technologies entered into a definitive agreement to acquire Biocare Medical, a global provider of clinical and research pathology solutions, for $950 million in an all-cash transaction. The acquisition expands Agilent’s pathology portfolio—particularly in immunohistochemistry (IHC)—and is expected to be accretive to Agilent’s top-line growth rate, margin profile, and non-instrument revenue mix in Year 1.
Quantum Surgical has acquired NeuWave Medical and combined both businesses under a newly created parent, Precision IO Group Inc., to expand a robotic-assisted tumor ablation platform. The deal is supported by investment from Ally Bridge Group and aims to integrate Quantum Surgical's Epione robotic system with NeuWave's microwave ablation technology to broaden access to minimally invasive interventional oncology care.
Zavation Medical Products, a portfolio company of Gemspring Capital, acquired ChoiceSpine Holdings, a Knoxville, Tennessee designer and manufacturer of spinal implant systems. ChoiceSpine will maintain its brand and operations as the companies work toward a unified organization; terms were not disclosed.
Tactile Systems Technology (doing business as Tactile Medical) acquired LymphaTech, Inc. for an upfront cash payment of $6.8 million plus potential milestone-based consideration to expand its lymphedema solutions into digital and connected care. LymphaTech co-founders joined Tactile to support commercial adoption and R&D as Tactile integrates the company’s 3D measurement and monitoring platform into its portfolio.
Natus Sensory has acquired TheraB Medical, a medical technology company focused on neonatal jaundice treatment using wearable phototherapy. The deal expands Natus Sensory’s newborn care portfolio with SnugLit, a FDA-cleared swaddle-style phototherapy system designed to support family-centered care while delivering continuous therapy.
Full Export
Get the full acquisitions list for this page as CSV + XLSX.
Find buyers actively acquiring medical devices companies.